The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
About bloody time so happy for all involved!! let’s hope we all get rewarded for holding through this shakedown
I agree 99. I suspect there are a number of swim lanes on the project plan - things are running in parallel, rather than waiting for one to end for the next to start, but there will be specific milestones required to trigger the news. Viruses (of numerous varieties) won't be finishing in early 2021.
Hahaha. Nah man 2 stocks only atm and ODX isn't and never was in my portfolio.
A treatment for not just Covid, but all viruses, potential here is huge and the bears know it.
@migs, spoken like a true ODX holder.
Taverham I'll happily be wrong. I tend to try to not get carried away with announcements as it hasn't bode well in the past and have been bitterly disappointed. Here's to a good day, week and month and me being very wrong!
@widows, I suggest you start rifling through your managers desk drawers looking for evidence for who its being made for. Then you will find hour answer.
Same Dumbpunter :)
Migsm, I disagree - this is major because it will allow access around the world- so good news fpr patients and also is a 3rd party endorsement by a credible company who's resputation is extremely important. If you read it again crefully you will also see the partner is not cliniport!
Wow I’m am currently working at a large drug Manufacturer where they are spending millions on a Covid-19 production line this is all I know but could it be SNG’s Therapeutic
Just had a quick skim through as I have to dash out, looks great.
Is just a partner to help distribute the drug ?
If so, are we to get an update as to where we actually are with the status of SNG0001, ie more trials or eua etc.
Does this indicate emergency approval in the UK and EU is almost imminent?
Richard Marsden, Chief Executive Officer of Synairgen, commented: "We are working tirelessly to progress SNG001 through the required clinical and regulatory channels to make this potentially critical treatment widely available to COVID-19 patients around the world. In the meantime, we are delighted to partner with Clinigen, whose extensive European experience and regulatory expertise will support access to treatment with SNG001 for hospitalised patients who most urgently need it."
Is this is a typo? Or does a treatment indicate 14 doses? I thought we have been aiming for a few million doses by end of the year?
Manufacturing Scale Up
In preparation for gaining approvals for SNG001, the Company has made good progress with discussions with a variety of international suppliers to scale up production of SNG001 rapidly, with the aim of being able to produce approximately 100,000 treatments per month in 2021.
Managed was programmes Made clinigen website
Cliniport is a safe and secure online ordering platform specifically designed to help healthcare professionals and pharmaceutical/biotechnology companies enrol their patients in Early Access Programs – sometimes called Managed Access Programs or Special Access Programs – that provide access to innovative, pre-approval medicines direct from the pharmaceutical manufacturer.
See why over 14,000 physicians and pharmacists use Cliniport to source medicines. Cliniport also brings invaluable benefits to pharmaceutical/biotechnology companies by offering managed access data and product information in real time. Cliniport can also be tailored to manage your specific needs, ultimately helping you to help patients more effectively.
Vox, here and there website. Must just be a few mins behind. The first is through now :)
Where? It’s not on here or there website?
ynairgen and Clinigen sign Managed Access Program agreement with SNG001 for treatment of hospitalised patients with COVID-19
Southampton and Burton-on-Trent, UK - 29 September, 2020: Synairgen plc (AIM: SNG, 'Synairgen'), the respiratory drug discovery and development company and Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company, have signed an agreement to launch a Managed Access Program for Synairgen's inhaled formulation of interferon beta (IFN-beta), SNG001, in the UK and the EU for the treatment of hospitalised COVID-19 patients.
SNG001 is an inhaled formulation of IFN-beta for direct delivery to the lungs via nebulisation. Synairgen announced positive topline data generated from 101 patients hospitalised with COVID-19 in its phase II trial, SG016, on the 20 July 2020. The trial of SNG001 in hospitalised patients produced very encouraging findings; patients who received SNG001 were more than twice as likely to recover over the course of the treatment period compared to those receiving placebo. Synairgen is currently in discussions with regulatory agencies to progress this potential COVID-19 treatment.
Richard Marsden, Chief Executive Officer of Synairgen, commented: "We are working tirelessly to progress SNG001 through the required clinical and regulatory channels to make this potentially critical treatment widely available to COVID-19 patients around the world. In the meantime, we are delighted to partner with Clinigen, whose extensive European experience and regulatory expertise will support access to treatment with SNG001 for hospitalised patients who most urgently need it."
Shaun Chilton, Clinigen Chief Executive Officer, added: " We are working with a number of companies who have products being tested against COVID-19 and are very pleased to be working with Synairgen to make this highly promising COVID-19 treatment available internationally. The early study results demonstrate that SNG001 may have a vital role in helping hospitalised patients recover more quickly from the disease."
Healthcare professionals in the EU can obtain details about the SNG001 Managed Access Program
by calling the customer service team at +44 (0) 1283 494 340 or emailing medicineaccess@clinigengroup.com .
Patients seeking information should contact their physician.
- Ends -
managed trial